Unilife — Shareholder Meeting (December 2012)
32 slides from Unilife's shareholder meeting presentation, Dec 3, 2012
Slide 1: Annual General Meeting of Stockholders
Annual General Meeting of Stockholders November 29, 2012 NASDAQ (UNIS) and ASX (UNS) Exhibit 99.1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-lo
Slide 3: Chairman's Welcome
Chairman's Welcome Jim Bosnjak OAM NASDAQ (UNIS) and ASX (UNS)
Slide 4: Introducing our Board of Directors In Attendance
Introducing our Board of Directors In Attendance Alan Shortall CEO Executive Director since 2002 Mary Kate Wold, J.D. Non-Executive Director since 2010 Chair of Strategic Partnerships Committee John Lund, CPA Non-Executive Director since 2009 Chair of Audit Committee William Galle Non-Executive Dire
Slide 5: Introducing our Board of Directors Apologies
November 29, 2012 Introducing our Board of Directors Apologies Jeff Carter MApp. BFin Non-Executive Director since 2006 Based in Australia Marc Firestone, J.D. Non-Executive Director since 2010 Chair of Nominating and Corporate Governance Committee Chair of Audit Committee
Slide 6: Agenda
Agenda Confirmation of Quorum Resolutions Presentation from the CEO Questions Confirmation of Results Other Business
Slide 7: Resolutions
Resolutions November 29, 2012 1.1 Elect Director Slavko James Joseph Bosnjak 1.2 Elect Director Jeff Carter 1.3 Elect Director William Galle 1.4 Elect Director John Lund 1.5 Elect Director Mary Katherine Wold 1.6 Elect Director Alan D. Shortall 2 Ratify Auditors 3 Advisory Vote to Ratify Named Execu
Slide 8: Confirmation of Quorum
Confirmation of Quorum Unilife's quorum requirement is one-third of outstanding shares being represented either in person or by proxy At least 54% of the total outstanding shares entitled to vote have been received and are represented by person or proxy
Slide 9: Presentation by Mr. Alan Shortall, CEO
Presentation by Mr. Alan Shortall CEO NASDAQ (UNIS) and ASX (UNS)
Slide 10: Broad, Expanding Portfolio of Device Platforms
November 29, 2012 Broad, Expanding Portfolio of Device Platforms Prefilled Syringes $2B market (12-15% CAGR) Drug Reconstitution $500MM (20-30%+ CAGR) Auto-Injectors $1B market (15-25% CAGR) Injection Pumps $500MM (30-50%+ CAGR) Targeted Delivery $250MM (20-30% CAGR) Unifill Syringe EZMix (tm) Lisa
Slide 11: Diversified, Expanding Base of Customers
November 29, 2012 November 29, 2012 Diversified, Expanding Base of Customers
Slide 12: A Glimpse into our Commercial Pipeline
A Glimpse into our Commercial Pipeline Device Platform No. of programs No. of customers No. programs with 2013 revenues targeted Cumulative peak annual sales ($MM) Prefilled syringes 10 10 5 $315 Bolus Injectors (pumps) 8 6 4 $372 Auto-injectors 3 3 1 $65 Drug reconstitution 5 5 1 $120 Targeted deli
Slide 13: Prefilled Syringes with Integrated Safety
Prefilled Syringes with Integrated Safety November 29, 2012 Unifill(r) syringe Unifill(r) Select Automatic Retraction USP-Compliant Per Standard Handling Intuitive Steps of Use Auto Needle Lockout A unique best-in-class platform to serve the delivery needs of virtually all prefilled drugs and vaccin
Slide 14: Unifill Platform - Commercial Pipeline
Unifill Platform - Commercial Pipeline Device Drug Status Next Value Event First Targeted Revenue Target Launch Peak Annual Sales Per Contract $MM Customer Designation Unifill Approved Supply contract 2013 2014 $70 A Unifill Approved Regulatory submission 2013 2014 $15 B Unifill Late-Stage Clinical
Slide 15: Liquid / Dry Combinations Drug Reconstitution Delivery Systems
Liquid / Dry Combinations Drug Reconstitution Delivery Systems 2-Step Reconstitution Automatic Retraction Intuitive Steps of Use Uniquely Ventless A game-changing technology for the reconstitution and delivery of liquid or dry drug combination therapies EZMix(tm) syringe EZMix(tm) Select
Slide 16: Drug Reconstitution - Commercial Pipeline
Drug Reconstitution - Commercial Pipeline Device Drug Status Next Value Event First Target Revenues Target Launch Peak Annual Sales Per Contract $MM Customer Designation EZMix Late-stage Clinical development contract 2013 2015 20 E EZMix Late-stage Clinical development contract 2014 2017 20 D EZMix
Slide 17: Auto-Injectors
Auto-Injectors Our elegant, intuitive auto-injectors have true end-of-dose indicators and can address specific drug and patient needs LISA Reusable Auto- Injector RITA Disposable Auto- Injector Today shipping LISA to a large cap customer as prelude to Clinical development contract
Slide 18: Auto-Injectors - Commercial Pipeline
Auto-Injectors - Commercial Pipeline A selection of our active programs Drug Status Next Value Event First Target Revenues Target Launch Peak Annual Sales Per Contract $MM Customer Designation LISA Late-stage Clinical development contract 2013 2015 20 D LISA Late-stage Clinical development contract
Slide 19: Bolus Injectors and Infusion Pumps
Bolus Injectors and Infusion Pumps November 29, 2012 From 1mL - 30mL dose volumes Suitable for Bolus or Rate-Based Therapies Standard Handling and Materials in Fluid Path Safe, Ergonomic and Intuitive Design Many Customization Options A platform of wearable, disposable devices for the long-duration
Slide 20: Injection Pumps - Commercial Pipeline
Injection Pumps - Commercial Pipeline A Selection of our Most Active Programs Drug-Status Next Value Event First Target Revenues Target Launch* Peak Annual Sales Per Contract $MM Customer Designation Late-stage Clinical development contract 2013 2015 75 C Late-stage Clinical development contract 201
Slide 21: Targeted Delivery Systems
Targeted Delivery Systems November 29, 2012 Depot-ject(tm) Ocu-ject(tm) Innovative devices to accurately inject novel therapies requiring localized or targeted delivery of doses to the eye or other organs
Slide 22: Targeted Delivery Systems - Commercial Pipeline
Targeted Delivery Systems Device Drug Status Next Value Event First Target Revenues Target Launch Peak Annual Sales Per Contract $MM Customer designation Ocu-ject Late-stage Clinical development contract 2013 2015 $20 D Ocu-ject Late-stage Clinical development contract 2014 2016 $20 P Organ delivery
Slide 23: Summary of our Commercial Pipeline
Summary of our Commercial Pipeline More than 30 active programs with 20 customers now at an advanced status with significant value events in progress More than a dozen programs covering every device platform to begin generating near-term revenues in 2013 Clinical development programs for all Unilife
Slide 24: Summary
Summary Unilife has never been in a stronger position than today The commercial potential for Unilife is greater than ever Business strategy is being fully executed, in most cases ahead of schedule and resonating strongly with customers Building tremendous value that will be recognized via a series
Slide 25: Questions
a oa Questions uniure?
Slide 26: Consider and Vote for Matters set forth in Proxy Statement
Consider and Vote for Matters set forth in Proxy Statement NASDAQ (UNIS) and ASX (UNS)
Slide 27: Election of Directors
Election of Directors Item 1. For For Withheld Withheld Item 1.1 Jim Bosnjak 36,950,413 96.54% 1,324,051 3.46% Item 1.2 Jeff Carter 36,414,906 95.14% 1,859,558 4.86% Item 1.3 William Galle 37,388,860 97.69% 885,604 2.31% Item 1.4 John Lund 37,330,534 97.53% 943,930 2.47% Item 1.5 Mary Kate Wold 37,8
Slide 28: Item 2. Ratification of KPMG LLP as Auditor
Item 2. Ratification of the appointment of KPMG LLP as the Corporation's independent registered public accounting firm for Fiscal Year 2013 For Against Abstain Item 2. 44,650,235 (99.1%) 344,269 (0.76%) 64,985 (0.14%)
Slide 29: Item 3. Advisory Vote on Executive Compensation
Item 3. For Against Abstain Item 3. 26,468,008 (69.15%) 11,509,238 (30.07%) 297,218 (0.78%) To consider and act on an advisory vote regarding the approval and compensation paid to certain executive officers
Slide 30: Item 4. Ratification of Issuance and Sale of Common Stock
Item 4. For Against Abstain Item 4. 37,306,982 (97.48%) 855,402 (2.23%) 112,080 (0.23%) To consider and act on the ratification of the issuance and sale by the Company of 6,154,000 shares of the Company's common stock in June 2012
Slide 31: Other Business
Other Business NASDAQ (UNIS) and ASX (UNS)
Slide 32: Close of Meeting
Close of Meeting NASDAQ (UNIS) and ASX (UNS)